Privia Health Group, Inc. (PRVA): what the price requires

Generated: 2026-07-14 · Exported: 2026-07-16 · Source: https://boothcheck.com/report/PRVA

Headline

Field	Value
Ticker	PRVA
Company	Privia Health Group, Inc.
Current price	$27.78/sh

What The Price Requires (Inversion)

The assumption today's price embeds, recovered by inverting the valuation.

Field	Value
Inversion basis	whole-company
Operating margin today	1.4%
Must persist for	17.1y
Multiple paid	102x operating income

Solve inputs: computed at a 10.1% cost of capital; growth searched up to the 25% self-funding ceiling; each 1pp moves the implied horizon ~2.5 years.

How unusual the bet is: elevated

Reference	Value
vs own history	+0.52σ
sustained it ~10 years at this level	14%
implied end-window share	0%

Valuation X-Ray

Asset, earnings-power and peer-multiple models all land far below the price; ONLY the growth-DCF reaches it. The bet is durable compounding the static frames structurally cannot price (a moat/durability premium).

How the valuation models price the stock relative to the market price. Price/FV above 1.0 means the market pays more than that lens defends (expensive); at or below 1.0 the lens can defend the price.

Family	Median price/FV	Models	Reads
Asset	10.68x	2	expensive
Earnings	4.22x	4	expensive
Relative	3.74x	5	expensive
Growth	0.77x	3	justifies

Families that justify the price: Growth Families that call it expensive: Asset, Earnings, Relative

The models below discount at their own flat-beta convention rates (cost of equity 9.3%, WACC 9.2%); the inversion above states its own rate.

Per-Model Detail (n=14)

Model	Family	FV	Price/FV	Applicable	Methodology
DCF Perpetual Growth	Growth	$47.86	0.58x	yes	FCF base $0.2B, growth 25% (input: historical growth), terminal g 4.0%, WACC 9.2%, 7yr projection
DCF Exit Multiple	Growth	$36.20	0.77x	yes	Exit EV/EBITDA: 65.8x / 67.8x / 69.8x (bear / base = today's held flat / bull), 7yr
Relative Valuation	Relative	$10.30	2.70x	yes	P/E 39.6x (blended: static sector reference 18x + trailing (TTM) 167x), scenarios: 31.8x / 39.6x / 47.4x (bear / base = reference held flat / bull), EV/EBITDA 26.4x
Simple DDM	Growth	—	—	no	—
Two-Stage DDM	Growth	—	—	no	—
Simple Excess Return	Asset	$1.80	15.43x	yes	BV/sh $5.75, ROE (TTM) 2.9%, ke 9.3%
Two-Stage Excess Return	Asset	$1.07	25.96x	yes	5yr excess ROE then converge to ke=9.3% (excluded from median)
Discounted Future Market Cap	Growth	$35.37	0.79x	yes	Rev $2.2B, growth 25% (input: historical growth; tapered), Terminal P/S: 1.3x / 1.6x / 1.9x (bear / base = today's held flat / bull, cap 12x)
Peter Lynch Fair Value	Relative	$5.95	4.67x	yes	EPS $0.17, growth 35% (input: historical EPS growth), PEG=4.77 (Overvalued)
Margin Trajectory	Growth	—	—	no	—
Earnings Power Value	Earnings	—	—	no	—
Residual Income	Asset	$0.79	35.16x	yes	BV $5.75 + 5yr PV of (ROE (TTM) 2.9% − Kₑ 9.3%) × BV; BV grows 1.9%/yr (excluded from median)
Graham Number	Asset	$4.69	5.92x	yes	√(22.5 × EPS $0.17 × BVPS $5.75) — Graham's conservative floor
EV/EBITDA Relative	Relative	$7.43	3.74x	yes	EBITDA $0.05B × sector EV/EBITDA 12.0x
FCF Yield	Earnings	$14.45	1.92x	yes	FCF $138.0M / Kₑ 9.3% — zero-growth perpetuity
SBC-Adj FCF Yield	Earnings	$8.24	3.37x	yes	SBC-adj FCF $0.06B (FCF $0.14B − SBC $0.08B) capitalized at Kₑ
Ben Graham Formula	Earnings	$5.49	5.06x	yes	EPS $0.17 × (8.5 + 2×15.0%) × (4.4 / 5.3%)
ROIC-Justified P/B	Asset	$1.04	26.71x	yes	BV $5.75 × (ROIC 1.7% / WACC 9.2%) (excluded from median)
P/Sales Sector	Relative	$42.91	0.65x	yes	Revenue $2.25B × sector P/S 2.5x
PEG Fair Value	Relative	$6.37	4.36x	yes	EPS $0.17 × (PEG 1.5 × growth 25.0% (input: historical EPS growth)) → PE 37.5x
Earnings Yield	Earnings	$1.84	15.10x	yes	EPS $0.17 / required return 9.3% (Rf 4.3% + ERP 5.0%)
Funds From Operations Multiple	Relative	—	—	no	—
Clinical Phase NPV	Growth	—	—	no	—
Merton	Asset	—	—	no	—
V5 Mechanical	—	—	—	no	—

Solvency

Field	Value
Net cash	$419.5m
Net debt / NOPAT (after-tax)	-17.48x (net cash)
Net debt / operating income (pre-tax)	-13.81x (net cash)
Share count CAGR (dilution)	4.9%
Burning cash	no

Interest expense is not separately reported in the latest filings, so interest coverage cannot be computed.

Bullet Takeaways

• The business is capital-light and debt-free, with about $420 million in net cash and no gross debt. That balance sheet, plus a model that adds physicians without buying their practices, is the structural advantage the bull case rests on.
• At about $24 the price is rich on every static frame. The market pays roughly 85 times operating income, which implies growth held at a self-funding ceiling for about 16 years. Only the growth-DCF reaches the price; asset, earnings-power, and peer-multiple frames all sit far below it.
• First-quarter 2026 showed strong operations and weak per-share profit: revenue up 25.8% and adjusted EBITDA up 36.3%, but non-GAAP EPS of $0.02 missed the roughly $0.08 estimate. Management maintained 2026 guidance and raised its attributed-lives range.

Bull Case

The structural advantage that defines Privia is that it grows a physician network without owning the doctors' practices, which keeps capital intensity low and returns on deployed capital high. The model lets local practices keep their legacy identity while adopting the platform: the 10-K notes that affiliated "locations maintain their legacy brand, but also adopt the overarching Privia Medical Group brand" (FY2025 10-K, accession 0001759655-26-000010). That is a powerful flywheel. Privia provides the technology, payer contracting, and value-based-care infrastructure; the physicians bring the patients. The result is visible in the numbers, with first-quarter adjusted EBITDA up 36.3% to $36.7 million and EBITDA as a share of care margin expanding 290 basis points to 28.5%. Operating leverage like that, on a near-zero-debt balance sheet with about $420 million of net cash, is the moat the bull case leans on.

The demand backdrop is a multi-decade tailwind. The United States is shifting away from fee-for-service toward value-based care, and the 10-K frames the opportunity directly, citing healthcare spending growing as a share of "GDP by 2033, according to CMS, outpacing average GDP growth" and the historical reliance on "reactive care to acute events" that value-based models aim to fix (accession 0001759655-26-000010). Privia is positioned to monetize that shift as it moves practices up the risk curve. The company says it intends to "increase the risk levels of our value" arrangements and grow "attributed patients in existing and new markets" (accession 0001759655-26-000010). Higher risk-bearing, done well, means a larger share of the savings flows to Privia.

The first quarter showed the growth engine running hard. Revenue rose 25.8% to $603.85 million, practice collections grew 14.6% to $914.8 million, and implemented providers increased 13.6% year over year, with 155 added sequentially. Attribution growth was strong enough that management raised its attributed-lives guidance even as it held the rest. For a platform business, provider count and attributed lives are the leading indicators, and both are accelerating. With no debt to service and cash to fund expansion or acquisitions, Privia can keep adding density to its markets, which is where the compounding the price is reaching for would come from.

Bear Case

The uncomfortable qualitative truth about Privia is that the headline growth has not turned into per-share profit, and the first quarter made that gap impossible to ignore. Revenue grew almost 26% and adjusted EBITDA grew 36%, yet non-GAAP EPS came in at $0.02 against a roughly $0.08 estimate. The operation is scaling; the bottom line per share is not keeping up. That matters because the price embeds a great deal of future profit, and the evidence in front of investors is that converting growth into GAAP earnings is harder than the operating slides suggest. A share count that has been rising about 5% a year only widens the distance between business growth and per-share value.

The valuation makes that disconnect the whole story. At roughly 85 times operating income, the asset, earnings-power, and peer-multiple frames all read the price as richly valued; only the growth-DCF reaches it. The inversion's own reasonable-growth band centers near $8 against a market price around $24 (June 27, 2026), and the reliability on that solve is flagged low. The price requires growth held at a self-funding ceiling for about 16 years, and history is unkind to that bet: only about 14% of comparable fast-growers sustained this kind of run for even ten years. The rate is within what Privia has delivered; the duration is the stretch, and durations are what disappoint.

The competitive and regulatory setting offers no protection for the multiple. Privia competes "in a highly fragmented and competitive U.S. healthcare industry" (FY2025 10-K, accession 0001759655-26-000010), against other enablers, payers building their own provider platforms, and large systems. The economics depend on risk-adjusted premium payments, which the company calculates "using diagnosis data" submitted "to payers (and ultimately to CMS)" (accession 0001759655-26-000010), so policy changes to Medicare Advantage rates or risk-coding rules feed straight into the model. The 10-K also flags professional liability exposure that "could result in an increase of professional liability insurance premiums" (accession 0001759655-26-000010). A company priced for sixteen years of uninterrupted compounding has no cushion if reimbursement tightens or growth simply normalizes.

Valuation

Privia is a clear expectations stock, and the inversion shows why. At about $24 the price works out to roughly 85 times company-wide operating income, which solves to growth held at a 25% self-funding ceiling for about 16 years, computed at a 10.1% cost of capital. The current operating margin is a thin 1.6%, so almost all of the value being paid for today is future margin and scale that have not yet arrived. Each percentage point of growth assumption moves the implied horizon by more than two years, which makes the solve sensitive, and the reliability is flagged low precisely because there is little earnings base to anchor against.

The family spread is lopsided in the way that defines a durability bet. The asset frame sits about nine times below price, the earnings-power frame more than three times below, and the peer-multiple frame roughly three times below. Only the growth-DCF reaches the current level. The reasonable-growth band centers near $8 with a high under $9, far beneath the market. That is not a contradiction to resolve; it is the signal. The price is isolating a compounding-and-moat premium that no current-earnings or current-book method can capture, which is appropriate for a capital-light platform but also means the static methods give no floor.

The honest read is that you are underwriting a long, clean runway. The near-term growth pace is within Privia's own record, the balance sheet is debt-free with real cash, and the operating leverage is improving. But the first quarter showed how slowly the growth is converting to per-share earnings, and the price assumes that conversion both happens and persists for well over a decade. The appropriate posture is to weigh what that price requires, not to treat the growth model's reach as a target, and to size the position to a bet that has no valuation support beneath it if the duration falls short.

Catalysts

The most recent quarter framed the near-term debate. First-quarter 2026 revenue of $603.85 million beat the roughly $592 million consensus and rose 25.8% year over year, and adjusted EBITDA grew 36.3% to $36.7 million, but non-GAAP EPS of $0.02 fell well short of the roughly $0.08 estimate. Management maintained its 2026 guidance across metrics and raised the range for attributed lives on strong first-quarter attribution. The next earnings reports are the key checkpoints for whether the gap between operating growth and per-share profit starts to close.

The operating catalysts are the platform's leading indicators. Provider implementations grew 13.6% year over year with 155 added sequentially, and practice collections rose 14.6%, so continued growth in implemented providers and attributed lives is what the bull case watches. The move up the risk curve is the higher-leverage catalyst: as Privia takes on more value-based risk, a larger share of generated savings can flow to the company, which is where margin expansion would accelerate. Entry into new markets and tuck-in acquisitions funded by the cash balance are the other growth levers.

The risks are mostly policy and reimbursement. The economics depend on Medicare Advantage rates and risk-adjustment rules, so any tightening from CMS would pressure the model directly. The fragmented competitive landscape means margin discipline cannot be taken for granted, and professional liability costs can rise. For a stock priced for many years of compounding, a normalization in growth, a reimbursement headwind, or another quarter where revenue scales but per-share earnings do not would each be enough to challenge the price.

Peer Cohorts (Per Segment, With Filing Citations)

Privia Health (single segment) (reported)

• LFST (LifeStance Health Group, Inc.)
• (no filing in the citation store)
• HIMS (HIMS & HERS HEALTH, INC.)
• (no filing in the citation store)

Methodology Note

• Priced-in inversion: the valuation is inverted on the current price to recover the operating-income growth, duration, and steady-state margin the price embeds (ROE for financials, FFO growth for REITs).
• Valuation x-ray: the valuation models, grouped into four families (asset, earnings, relative, growth). Each model is expressed as a price/FV ratio (distance from price), not a point fair-value estimate. The spread across families is the disagreement.
• Solvency: net cash/debt, net-debt-to-NOPAT, interest coverage, and share-count CAGR from EDGAR financials (net debt / FFO and fixed-charge coverage for REITs; regulatory-capital framing for financials).
• Peer cohorts: per-segment comparables with deep-linkable SEC filing citations.

Fundamentals sourced from SEC EDGAR filings. Current price from Databento. The priced-in inversion and valuation x-ray are computed by the boothcheck engine; narrative composed by AI from the structured data.